| Symbol | GMAB |
|---|---|
| Name | GENMAB A/S |
| Sector | HEALTH CARE |
| Region | Europe |
| Industry | - |
| Address | 10179 United States NY 383 Madison Avenue Floor 11 |
| Telephone | 1-800- 990-1135 |
| Fax | — |
| — | |
| Website | http://www.genmab.com |
| Incorporation | DK |
| Incorporated On | 1999 |
| Employees | — |
| Fiscal Year | 12/31 |
| Public Since | — |
| Exchanges | OTC;NASDAQ |
| Auditor | — |
| Audit Status | AUDITED |
| Reporting Status | U.S. Reporting: SEC Reporting |
| CIK | 0001434265 |
| Description | Genmab is an international biotechnology company specializing in the creation and development of differentiated human antibody therapeutics for the treatment of cancer. Additional info from NASDAQ: Additional info from OTC: |
2026-07-23 20:00
Genmab and AbbVie Provide Clarification on Phase 3 EPCORE® DLBCL-1 Trial Evaluating Epcoritamab (DuoBody®-CD3xCD20) in Patients with Relapsed/Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Read more
2026-07-06 17:59
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Read more
2026-07-06 17:45
Genmab Announces TEPKINLY® (epcoritamab) in Combination with Lenalidomide and Rituximab is Approved by the European Commission for the Treatment of Relapsed or Refractory Follicular Lymphoma
Read more
2026-06-29 20:15
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
Read more
2026-06-29 20:14
Genmab Announces Positive Phase 3 Results for Epcoritamab Plus Lenalidomide in Patients with Relapsed/Refractory Diffuse Large B-Cell Lymphoma, Demonstrating Statistically Significant Improvement in Progression-Free Survival
Read more
2026-06-13 16:45
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Read more
2026-06-13 16:45
Genmab Announces Epcoritamab Monotherapy and Epcoritamab-Based Combination Regimens Demonstrate High Response Rates in Elderly Patients with Newly Diagnosed Diffuse Large B-Cell Lymphoma (DLBCL)
Read more| Trial ID | Title | Phase | Indication | Status | Start Date | Completion Date | Source |
|---|---|---|---|---|---|---|---|
| NCT05692050 | Expanded Access to Epcoritamab | — | Lymphoma | No_Longer_Available | — | — | ClinicalTrials.gov |
| NCT01449357 | Zalutumumab in Non-Small Cell Lung Cancer (NSCLC) Patients Refractory to Tyrosi… | Phase2 | Non-small Cell Lung Cancer | Withdrawn | — | — | ClinicalTrials.gov |
| NCT05733650 | Expanded Access Program for Epcoritamab | — | Large B-cell Lymphoma | Approved_For_Marketing | — | — | ClinicalTrials.gov |
| NCT07714421 | Epcoritamab and Pola-R-mini-CHP for the Treatment of Diffuse Large B Cell Lymph… | Phase1 | Diffuse Large B-Cell Lymphoma | Not_Yet_Recruiting | 2026-12-08 | 2031-10-08 | ClinicalTrials.gov |
| NCT07702032 | Study of Petosemtamab Plus Chemotherapy Versus Cetuximab Plus Chemotherapy in R… | Phase3 | Left-sided Colorectal Cancer | Recruiting | 2026-08-01 | 2031-09-01 | ClinicalTrials.gov |
| NCT07564141 | Study to Assess the Efficacy and Safety of Rina-S With or Without Bevacizumab C… | Phase3 | Platinum-Sensitive Ovarian Cancer | Recruiting | 2026-08-01 | 2031-11-01 | ClinicalTrials.gov |
| NCT07695831 | A Phase 1 Trial of GEN1119 in Participants With Solid Tumors | Phase1 | Solid Tumours | Not_Yet_Recruiting | 2026-08-01 | 2029-06-01 | ClinicalTrials.gov |
| NCT07604766 | An Extension Study to Assess the Efficacy of Rina-S Compared to Treatment of In… | Phase3 | Platinum-resistant Ovarian Cancer | Not_Yet_Recruiting | 2026-06-01 | 2028-12-01 | ClinicalTrials.gov |
| NCT07539311 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Advanced… | Phase2 | Gastrointestinal Cancers | Recruiting | 2026-05-11 | 2028-11-01 | ClinicalTrials.gov |
| NCT07416123 | A Study of GEN1106 in Participants With Solid Tumors | Phase1 | Solid Tumors | Recruiting | 2026-04-14 | 2029-06-25 | ClinicalTrials.gov |
| NCT07387068 | Trial to Evaluate the Safety and Preliminary Efficacy of GEN1079 in Participant… | Phase1 | Advanced Solid Tumors | Recruiting | 2026-04-07 | 2031-01-01 | ClinicalTrials.gov |
| NCT07225270 | Study to Assess the Efficacy and Safety of Rina-S Plus Standard of Care Compare… | Phase3 | Ovarian Cancer | Recruiting | 2026-04-03 | 2030-05-01 | ClinicalTrials.gov |
| NCT07384715 | First-in-human (FIH) Trial of GEN3018 in Relapsed or Refractory (R/R) Acute Mye… | Phase1 | R/R AML | Recruiting | 2026-02-16 | 2030-04-20 | ClinicalTrials.gov |
| NCT07288177 | Study to Assess the Efficacy and Safety of Rina-S in Participants With Non-smal… | Phase2 | Non-small Cell Lung Cancer (NSCLC) | Recruiting | 2026-01-30 | 2028-11-22 | ClinicalTrials.gov |
| NCT06919939 | Epcoritamab in Combination With Loncastuximab Tesirine in Relapsed/Refractory L… | Phase2 | Large B-cell Lymphoma | Recruiting | 2026-01-07 | 2031-01-07 | ClinicalTrials.gov |
| NCT07166094 | Study to Assess the Efficacy and Safety of Rina-S Compared to Treatment of Inve… | Phase3 | Endometrial Cancer | Recruiting | 2025-11-28 | 2029-11-01 | ClinicalTrials.gov |
| NCT06796998 | Epcoritamab in Patients With Newly Diagnosed Marginal Zone Lymphoma (MZL) | Phase2 | Marginal Zone Lymphoma | Recruiting | 2025-10-13 | 2031-04-15 | ClinicalTrials.gov |
| NCT07108998 | Study of Epcoritamab as a Consolidation Therapy in CLL/SLL | Phase2 | CLL/SLL | Recruiting | 2025-08-22 | 2029-07-01 | ClinicalTrials.gov |
| NCT07030699 | A Study of Epcoritamab With Lenalidomide and Tafasitamab in People With Diffuse… | Phase2 | Lymphoma | Withdrawn | 2025-08-13 | 2026-03-31 | ClinicalTrials.gov |
| NCT06984328 | Study of the Effectiveness and Safety of Acasunlimab Alone and With Pembrolizum… | Phase2 | Cutaneous Melanoma | Terminated | 2025-07-25 | 2026-05-15 | ClinicalTrials.gov |
| NCT06672705 | Epcoritamab for the Treatment of Relapsed or Refractory Post Transplant Lymphop… | Phase1 | Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder | Recruiting | 2025-06-16 | 2026-12-31 | ClinicalTrials.gov |
| NCT06811272 | Outpatient Epcoritamab as 2L in NTE R/R DLBCL | Phase2 | Relapsed Large B-cell Lymphoma | Recruiting | 2025-06-05 | 2028-10-01 | ClinicalTrials.gov |
| NCT06830759 | Real-World Study to Assess Subcutaneous Epcoritamab in Adult Participants With … | — | Diffuse Large B-cell Lymphoma | Recruiting | 2025-03-28 | 2031-09-01 | ClinicalTrials.gov |
| NCT06619236 | Study to Assess the Efficacy of Rina-S Compared to Treatment of Investigator's … | Phase3 | Platinum-resistant Ovarian Cancer | Active_Not_Recruiting | 2025-02-07 | 2028-05-23 | ClinicalTrials.gov |
| NCT06771921 | A First-in-Human Trial of Safety and Efficacy of GEN1078 in Participants With S… | Phase1 | Malignant Solid Tumor | Terminated | 2025-01-29 | 2025-06-11 | ClinicalTrials.gov |
| NCT06563596 | Epco, Zanu, Ritux for R/R FL or MZL | Phase2 | Follicular Lymphoma | Recruiting | 2025-01-21 | 2030-03-01 | ClinicalTrials.gov |
| NCT06447376 | Study of Cytokine Release Syndrome Prophylaxis and Treatment With Siltuximab Pr… | Phase1 | Non-Hodgkin Lymphoma | Recruiting | 2025-01-14 | 2028-09-01 | ClinicalTrials.gov |
| NCT06510491 | Epcoritamab in Previously Treated WM | Phase2 | Waldenstrom Macroglobulinemia | Recruiting | 2024-12-06 | 2027-12-31 | ClinicalTrials.gov |
| NCT06635824 | Trial to Evaluate Acasunlimab and Pembrolizumab Combination Superiority Over St… | Phase3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | Active_Not_Recruiting | 2024-11-25 | 2028-09-30 | ClinicalTrials.gov |
| NCT06510361 | Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Up… | Phase2 | Lymphoma | Recruiting | 2024-11-20 | 2028-05-01 | ClinicalTrials.gov |
| NCT06685068 | A Phase 1/2 Study of GEN1286 in Patients With Advanced Solid Tumors | Phase1 | Advanced Solid Tumor | Terminated | 2024-11-13 | 2026-03-12 | ClinicalTrials.gov |
| NCT06458439 | Epcoritamab-CAR T Cells for Large B-cell Lymphomas | Phase2 | Lymphoma, Non-Hodgkin | Recruiting | 2024-09-24 | 2027-12-01 | ClinicalTrials.gov |
| NCT06573294 | Trial to Assess the Safety and Antitumor Activity of GEN1057 in Malignant Solid… | Phase1 | Advanced Malignant Solid Tumors | Terminated | 2024-08-28 | 2026-04-07 | ClinicalTrials.gov |
| NCT06508658 | A Study of Subcutaneously Injected Epcoritamab Plus Oral Lenalidomide Tablets C… | Phase3 | Diffuse Large B-Cell Lymphoma | Active_Not_Recruiting | 2024-08-13 | 2028-03-01 | ClinicalTrials.gov |
| NCT06391775 | Trial to Assess the Safety and Preliminary Efficacy of GEN1055 on Malignant Sol… | Phase1 | Malignant Solid Tumor | Terminated | 2024-05-14 | 2025-11-20 | ClinicalTrials.gov |
| NCT06191744 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and… | Phase3 | Follicular Lymphoma (FL) | Active_Not_Recruiting | 2024-02-05 | 2037-11-01 | ClinicalTrials.gov |
| NCT06171789 | PRO1107 in Patients With Advanced Solid Tumors | Phase1 | Endometrial Cancer | Terminated | 2024-01-03 | 2025-08-18 | ClinicalTrials.gov |
| NCT06150183 | Safety and Preliminary Efficacy of BNT314 in Cancer Patients With Malignant Sol… | Phase1 | Advanced Malignant Solid Tumor | Active_Not_Recruiting | 2023-11-30 | 2028-03-01 | ClinicalTrials.gov |
| NCT06057038 | A Safety Trial of GEN1042 in Japanese Subjects With Malignant Solid Tumors | Phase1 | Malignant Solid Tumor | Active_Not_Recruiting | 2023-11-24 | 2027-08-01 | ClinicalTrials.gov |
| NCT05852717 | Safety and Efficacy of Epcoritamab With Gemcitabine, Dexamethasone, and Cisplat… | Phase2 | Large Cell Lymphoma, Diffuse | Recruiting | 2023-10-31 | 2028-11-24 | ClinicalTrials.gov |
| NCT06046274 | GEN1046 in Combination With Anticancer Agents for the Treatment of Advanced End… | Phase2 | Advanced Endometrial Cancer | Withdrawn | 2023-10-01 | 2028-06-01 | ClinicalTrials.gov |
| NCT06018129 | A First-in-human Trial of GEN3017 in Hodgkin Lymphoma and Non-Hodgkin Lymphoma | Phase1 | Classical Hodgkin Lymphoma | Terminated | 2023-09-21 | 2025-02-05 | ClinicalTrials.gov |
| NCT05848765 | Relapsed Follicular Lymphoma Randomised Trial Against Standard ChemoTherapy | Phase2 | Relapsed Follicular Lymphoma | Recruiting | 2023-09-04 | 2031-11-30 | ClinicalTrials.gov |
| NCT05783609 | Epcoritamab and Rituximab for First-line Follicular Lymphoma | Phase2 | Follicular Lymphoma | Recruiting | 2023-06-21 | 2030-02-01 | ClinicalTrials.gov |
| NCT05721222 | Trial of PRO1160 (GEN1160) in Relapsed or Refractory Non-Hodgkin Lymphoma (NHL)… | Phase1 | Renal Cell Carcinoma | Terminated | 2023-03-15 | 2025-11-05 | ClinicalTrials.gov |
| NCT05491317 | A Safety and Antitumor Activity Trial of Immunoradiotherapy Combinations as a T… | Phase1 | Non-CNS Tumor | Terminated | 2023-03-08 | 2025-08-11 | ClinicalTrials.gov |
| NCT05660967 | Subcutaneous Epcoritamab With or Without Lenalidomide as First Line Therapy for… | Phase2 | Diffuse Large B-Cell Lymphoma | Terminated | 2023-03-06 | 2026-06-10 | ClinicalTrials.gov |
| NCT05578976 | A Study to Evaluate Change in Disease Activity of Subcutaneous (SC) Epcoritamab… | Phase3 | Diffuse Large B-Cell Lymphoma | Active_Not_Recruiting | 2023-02-08 | 2029-12-01 | ClinicalTrials.gov |
| NCT05579366 | Rinatabart Sesutecan (Rina-S, PRO1184, GEN1184) for Advanced Solid Tumors (GCT1… | Phase1 | High Grade Epithelial Ovarian Cancer | Recruiting | 2022-12-07 | 2027-10-01 | ClinicalTrials.gov |
| NCT05586321 | Study of Safety and Antitumor Activity of GEN1056 in Participants With Advanced… | Phase1 | Solid Tumor, Adult | Completed | 2022-10-24 | 2025-10-23 | ClinicalTrials.gov |
| NCT07226752 | A Sub-study Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relap… | Phase3 | Diffuse Large B-Cell Lymphoma | Active_Not_Recruiting | 2022-10-08 | 2028-06-14 | ClinicalTrials.gov |
| NCT05206357 | Study of the Adverse Events and Change in Disease State of Pediatric Participan… | Phase1 | Non-hodgkin Lymphoma | Active_Not_Recruiting | 2022-10-04 | 2028-11-01 | ClinicalTrials.gov |
| NCT05435339 | A Study to Evaluate Safety, Tolerability, and Preliminary Effect of the GEN1053… | Phase1 | Solid Tumor, Adult | Terminated | 2022-10-04 | 2024-05-24 | ClinicalTrials.gov |
| NCT05409066 | Study of Subcutaneous Epcoritamab in Combination With Intravenous Rituximab and… | Phase3 | Follicular Lymphoma (FL) | Active_Not_Recruiting | 2022-09-20 | 2029-12-01 | ClinicalTrials.gov |
| NCT05451810 | A Study to Evaluate Adverse Events of Subcutaneous (SC) Epcoritamab Administere… | Phase2 | Diffuse Large B-Cell Lymphoma | Active_Not_Recruiting | 2022-08-17 | 2027-03-01 | ClinicalTrials.gov |
| NCT05283720 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneo… | Phase2 | Non-Hodgkin Lymphoma | Active_Not_Recruiting | 2022-06-14 | 2032-11-01 | ClinicalTrials.gov |
| NCT05201248 | A Study to Evaluate Adverse Events and Change in Disease Activity of Subcutaneo… | Phase1 | B-Cell Non-Hodgkin Lymphoma | Active_Not_Recruiting | 2022-03-10 | 2025-04-01 | ClinicalTrials.gov |
| NCT05180474 | GEN1047 for Solid Tumors - First in Human (FIH) Trial | Phase1 | Breast Cancer, Breast Neoplasms | Terminated | 2021-12-13 | 2026-03-25 | ClinicalTrials.gov |
| NCT05117242 | Safety and Efficacy Study of GEN1046 as a Single Agent or in Combination With P… | Phase2 | Non Small Cell Lung Cancer Metastatic | Active_Not_Recruiting | 2021-10-27 | 2027-05-27 | ClinicalTrials.gov |
| NCT04937153 | GEN1046 Safety and PK in Subjects With Advanced Solid Malignancies | Phase1 | Solid Tumor | Completed | 2021-06-15 | 2024-10-01 | ClinicalTrials.gov |
| NCT04824794 | GEN3014 Trial in Relapsed or Refractory Hematologic Malignancies | Phase1 | Relapsed or Refractory Multiple Myeloma (RRMM) | Terminated | 2021-03-09 | 2025-07-31 | ClinicalTrials.gov |
| NCT04697628 | Tisotumab Vedotin vs Chemotherapy in Recurrent or Metastatic Cervical Cancer | Phase3 | Cervical Cancer | Completed | 2021-02-22 | 2026-01-15 | ClinicalTrials.gov |
| NCT04628494 | A Phase 3 Trial of Epcoritamab vs Investigator's Choice Chemotherapy in Relapse… | Phase3 | Diffuse Large B-cell Lymphoma | Active_Not_Recruiting | 2021-01-13 | 2028-04-01 | ClinicalTrials.gov |
| NCT04623541 | Safety and Efficacy Study of Epcoritamab in Subjects With Relapsed/Refractory C… | Phase1 | Relapsed/Refractory Chronic Lymphocytic Leukemia | Active_Not_Recruiting | 2020-11-25 | 2028-02-01 | ClinicalTrials.gov |
| NCT04663347 | Safety and Efficacy Trial of Epcoritamab Combinations in Subjects With B-cell N… | Phase1 | Diffuse Large B-Cell Lymphoma | Active_Not_Recruiting | 2020-11-03 | 2027-09-30 | ClinicalTrials.gov |
| NCT04542824 | Trial of the Safety and Efficacy of Epcoritamab in Japanese Subjects With Relap… | Phase1 | Diffuse Large B Cell Lymphoma | Active_Not_Recruiting | 2020-08-20 | 2027-09-01 | ClinicalTrials.gov |
| NCT04424641 | A Study on the Safety of GEN1044 (DuoBody®-CD3x5T4) in Patients With Malignant … | Phase1 | Locally Advanced or Metastatic Solid Tumor(s) | Terminated | 2020-07-15 | 2021-10-29 | ClinicalTrials.gov |
| NCT04358458 | First-in-Human (FIH) Trial of GEN3009 in Subjects With Relapsed or Refractory B… | Phase1 | Diffuse Large B-cell Lymphoma | Terminated | 2020-03-13 | 2023-07-28 | ClinicalTrials.gov |
| NCT04083599 | GEN1042 Safety Trial and Anti-tumor Activity in Participants With Malignant Sol… | Phase1 | Malignant Solid Tumor | Active_Not_Recruiting | 2019-09-17 | 2027-01-01 | ClinicalTrials.gov |
| NCT03917381 | GEN1046 Safety Trial in Patients With Malignant Solid Tumors | Phase1 | Solid Tumors | Active_Not_Recruiting | 2019-05-14 | 2026-08-31 | ClinicalTrials.gov |
| NCT03657043 | A Study of Weekly Tisotumab Vedotin for Patients With Platinum-Resistant Ovaria… | Phase2 | Ovarian Cancer | Completed | 2019-03-20 | 2022-02-08 | ClinicalTrials.gov |
| NCT03913741 | A Trial of Tisotumab Vedotin in Japanese Subjects With Advanced Solid Malignanc… | Phase1 | Solid Tumor | Completed | 2019-02-27 | 2021-10-30 | ClinicalTrials.gov |
| NCT03625037 | First-in-Human (FIH) Trial in Patients With Relapsed, Progressive or Refractory… | Phase1 | DLBCL | Active_Not_Recruiting | 2018-06-26 | 2029-01-01 | ClinicalTrials.gov |
| NCT03438396 | A Trial of Tisotumab Vedotin in Cervical Cancer | Phase2 | Cervical Cancer | Completed | 2018-06-12 | 2022-08-02 | ClinicalTrials.gov |
| NCT03576131 | GEN1029 (HexaBody®-DR5/DR5) Safety Trial in Patients With Malignant Solid Tumors | Phase1 | Colorectal Cancer | Terminated | 2018-04-30 | 2021-10-12 | ClinicalTrials.gov |
| NCT03245736 | Tisotumab Vedotin Continued Treatment in Patients With Solid Tumors. | Phase2 | Ovary Cancer | Completed | 2017-08-23 | 2019-01-10 | ClinicalTrials.gov |
| NCT02988817 | Enapotamab Vedotin (HuMax-AXL-ADC) Safety Study in Patients With Solid Tumors | Phase1 | Ovarian Cancer | Completed | 2016-11-23 | 2021-11-12 | ClinicalTrials.gov |
| NCT02552121 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | Phase1 | Ovary Cancer | Completed | 2015-11-30 | 2017-12-13 | ClinicalTrials.gov |
| NCT02001623 | Tisotumab Vedotin (HuMax®-TF-ADC) Safety Study in Patients With Solid Tumors | Phase1 | Ovary Cancer | Completed | 2013-11-30 | 2019-05-02 | ClinicalTrials.gov |
| NCT01054625 | Zalutumumab Pharmacokinetics (PK) in Squamous Cell Carcinoma of the Head and Ne… | Phase1 | Head and Neck Cancer | Completed | 2010-03-01 | 2011-10-01 | ClinicalTrials.gov |
| NCT00802737 | Efficacy and Safety of Ofatumumab Retreatment and Maintenance Treatment in Pati… | Phase4 | Leukaemia, Lymphocytic, Chronic | Completed | 2009-01-01 | 2013-05-01 | ClinicalTrials.gov |
| NCT00707655 | Zalutumumab in Combination With Radiotherapy in Head and Neck Cancer Patients I… | Phase1 | Head and Neck Cancer | Terminated | 2008-09-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00677924 | Zalutumumab With or Without Irinotecan Chemotherapy in Cetuximab-Refractory Col… | Phase1 | Colorectal Cancer | Terminated | 2008-04-01 | 2009-04-01 | ClinicalTrials.gov |
| NCT00542308 | Zalutumumab in Non-curable Patients With SCCHN | Phase2 | Head and Neck Cancer | Completed | 2008-01-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00460551 | Zalutumumab in Combination With Chemo-Radiation in a Certain Type of Lung Cancer | Phase2 | Non Small Cell Lung Cancer | Terminated | 2007-04-01 | 2008-10-01 | ClinicalTrials.gov |
| NCT00401401 | Zalutumumab in Combination With Chemotherapy and Radiotherapy in Head and Neck … | Phase1 | Head and Neck Cancer | Terminated | 2006-12-01 | 2010-10-01 | ClinicalTrials.gov |
| NCT00382031 | Zalutumumab in Patients With Non-curable Head and Neck Cancer | Phase3 | Head and Neck Cancer | Completed | 2006-11-01 | 2011-08-01 | ClinicalTrials.gov |
| NCT00093041 | Zalutumumab in Head and Neck Cancer | Phase1 | Head and Neck Neoplasms | Completed | 2003-12-01 | 2005-01-12 | ClinicalTrials.gov |
| NCT00071084 | Clinical Trial of HuMax-CD4, a New Drug to Treat Advanced Stage T-Cell Lymphoma… | Phase2 | Cutaneous T-Cell Lymphoma | Completed | 2003-05-27 | 2004-06-29 | ClinicalTrials.gov |
| NCT00071071 | Clinical Trial of HuMax-CD4, a New Drug to Treat Early Stage T-Cell Lymphoma in… | Phase2 | Cutaneous T-Cell Lymphoma | Completed | 2003-04-30 | 2004-05-05 | ClinicalTrials.gov |
| NCT00042406 | Trial With HuMax-CD4 in Participants With Rheumatoid Arthritis (RA) Failing Tre… | Phase2 | Rheumatoid Arthritis | Terminated | 2002-03-04 | 2003-03-31 | ClinicalTrials.gov |
Total clinical trials: 91
| Product Name | Type | Development Stage | Therapeutic Area | Study Status | Trial ID |
|---|---|---|---|---|---|
| PLD | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | RECRUITING | NCT07564141 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | RECRUITING | NCT07564141 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | RECRUITING | NCT07564141 |
| Carboplatin | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | RECRUITING | NCT07564141 |
| Bevacizumab | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | RECRUITING | NCT07564141 |
| Rina-S | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | RECRUITING | NCT07564141 |
| Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts) | Drug | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03917381 |
| Acasunlimab in combination with pembrolizumab (in a separate expansion cohort) | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03917381 |
| Acasunlimab in combination with docetaxel (in a single expansion cohort) | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03917381 |
| Acasunlimab | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03917381 |
| GEN1079 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07387068 |
| 5-Fluorouracil | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06057038 |
| Carboplatin | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06057038 |
| Cisplatin | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06057038 |
| Pembrolizumab | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06057038 |
| GEN1042 | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06057038 |
| GEN3018 | Other | Phase PHASE1 | R/R AML | RECRUITING | NCT07384715 |
| Pirtobrutinib | Other | Phase PHASE1 | Relapsed/Refractory Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT04623541 |
| Lenalidomide | Other | Phase PHASE1 | Relapsed/Refractory Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT04623541 |
| Venetoclax | Other | Phase PHASE1 | Relapsed/Refractory Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT04623541 |
| rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone | Other | Phase PHASE1 | Relapsed/Refractory Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT04623541 |
| Epcoritamab | Other | Phase PHASE1 | Relapsed/Refractory Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT04623541 |
| IC | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT07166094 |
| Pembrolizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Bevacizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Carboplatin | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Rina-S | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Rina-S | Other | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07288177 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT06191744 |
| Obinutuzumab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT06191744 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT06191744 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT06191744 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT06191744 |
| Lenalidomide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT06191744 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT06191744 |
| Prednisone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT06191744 |
| Epcoritamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT06191744 |
| Bevacizumab | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07225270 |
| Rina-S | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07225270 |
| Rina-S | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT07166094 |
| Epcoritamab | Other | Phase PHASE1 | DLBCL | ACTIVE_NOT_RECRUITING | NCT03625037 |
| Rituximab and lenalidomide | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04542824 |
| Epcoritamab (maintenance) | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04542824 |
| Gemcitabine and oxaliplatin | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04542824 |
| Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04542824 |
| Epcoritamab | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04542824 |
| Epcoritamab (monotherapy) | Drug | Phase PHASE1 | Diffuse Large B Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04542824 |
| Rituximab and Lenalidomide | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| rituximab, ifosfamide, carboplatin, and etoposide phosphate | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| Lenalidomide | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| Epcoritamab | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| gemcitabine and oxaliplatin | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| rituximab and bendamustine | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| rituximab and lenalidomide | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| mFOLFOX6 | Other | Phase PHASE3 | Left-sided Colorectal Cancer | RECRUITING | NCT07702032 |
| FOLFIRI | Other | Phase PHASE3 | Left-sided Colorectal Cancer | RECRUITING | NCT07702032 |
| Cetuximab | Other | Phase PHASE3 | Left-sided Colorectal Cancer | RECRUITING | NCT07702032 |
| Petosemtamab | Other | Phase PHASE3 | Left-sided Colorectal Cancer | RECRUITING | NCT07702032 |
| Paclitaxel | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Pemetrexed | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Nab paclitaxel | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Gemcitabine | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| 5-FU | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Carboplatin | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Cisplatin | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Pembrolizumab | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| GEN1042 | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Docetaxel | Other | Phase PHASE3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | ACTIVE_NOT_RECRUITING | NCT06635824 |
| Pembrolizumab | Other | Phase PHASE3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | ACTIVE_NOT_RECRUITING | NCT06635824 |
| Acasunlimab | Other | Phase PHASE3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | ACTIVE_NOT_RECRUITING | NCT06635824 |
| GEN1119 | Other | Phase PHASE1 | Solid Tumours | NOT_YET_RECRUITING | NCT07695831 |
| Rina-S | Other | Phase PHASE2 | Gastrointestinal Cancers | RECRUITING | NCT07539311 |
| GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells. | Other | Phase PHASE1 | Breast Cancer, Breast Neoplasms | TERMINATED | NCT05180474 |
| PLD | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | RECRUITING | NCT07564141 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | RECRUITING | NCT07564141 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | RECRUITING | NCT07564141 |
| Carboplatin | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | RECRUITING | NCT07564141 |
| Bevacizumab | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | RECRUITING | NCT07564141 |
| Rina-S | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | RECRUITING | NCT07564141 |
| Rituximab | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | NOT_YET_RECRUITING | NCT07714421 |
| Prednisone | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | NOT_YET_RECRUITING | NCT07714421 |
| Positron Emission Tomography | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | NOT_YET_RECRUITING | NCT07714421 |
| Polatuzumab Vedotin | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | NOT_YET_RECRUITING | NCT07714421 |
| Magnetic Resonance Imaging | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | NOT_YET_RECRUITING | NCT07714421 |
| Epcoritamab | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | NOT_YET_RECRUITING | NCT07714421 |
| Doxorubicin | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | NOT_YET_RECRUITING | NCT07714421 |
| Cyclophosphamide | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | NOT_YET_RECRUITING | NCT07714421 |
| Computed Tomography | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | NOT_YET_RECRUITING | NCT07714421 |
| Biospecimen Collection | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | NOT_YET_RECRUITING | NCT07714421 |
| mFOLFOX6 | Other | Phase PHASE3 | Left-sided Colorectal Cancer | RECRUITING | NCT07702032 |
| FOLFIRI | Other | Phase PHASE3 | Left-sided Colorectal Cancer | RECRUITING | NCT07702032 |
| Cetuximab | Other | Phase PHASE3 | Left-sided Colorectal Cancer | RECRUITING | NCT07702032 |
| Petosemtamab | Other | Phase PHASE3 | Left-sided Colorectal Cancer | RECRUITING | NCT07702032 |
| Bevacizumab | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07225270 |
| Rina-S | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07225270 |
| GEN1119 | Other | Phase PHASE1 | Solid Tumours | NOT_YET_RECRUITING | NCT07695831 |
| Epcoritamab | Other | Phase PHASE2 | Large Cell Lymphoma, Diffuse | RECRUITING | NCT05852717 |
| GDP | Other | Phase PHASE2 | Large Cell Lymphoma, Diffuse | RECRUITING | NCT05852717 |
| AutoSCT OR CAR T-cell Therapy | Drug | Phase PHASE2 | Large Cell Lymphoma, Diffuse | RECRUITING | NCT05852717 |
| Pembrolizumab | Other | Phase PHASE2 | Cutaneous Melanoma | TERMINATED | NCT06984328 |
| Acasunlimab | Other | Phase PHASE2 | Cutaneous Melanoma | TERMINATED | NCT06984328 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Pegylated liposomal doxorubicin (PLD) | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Topotecan | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Rina-S | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Lenalidomide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT05409066 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT05409066 |
| Epcoritamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | ACTIVE_NOT_RECRUITING | NCT05409066 |
| GEN3018 | Other | Phase PHASE1 | R/R AML | RECRUITING | NCT07384715 |
| Pembrolizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Bevacizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Carboplatin | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Rina-S | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Rina-S | Other | Phase PHASE2 | Gastrointestinal Cancers | RECRUITING | NCT07539311 |
| IC | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT07166094 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06191744 |
| Obinutuzumab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06191744 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06191744 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06191744 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06191744 |
| Lenalidomide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06191744 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06191744 |
| Prednisone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06191744 |
| Epcoritamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06191744 |
| GEN1079 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07387068 |
| CC-99282 | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT05283720 |
| Polatuzumab Vedotin | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT05283720 |
| Prednisone | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT05283720 |
| Doxorubicin Hydrochloride [HCl] | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT05283720 |
| Cyclophosphamide | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT05283720 |
| Rituximab | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT05283720 |
| Ibrutinib | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT05283720 |
| Lenalidomide | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT05283720 |
| Epcoritamab | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | ACTIVE_NOT_RECRUITING | NCT05283720 |
| Docetaxel | Other | Phase PHASE3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | ACTIVE_NOT_RECRUITING | NCT06635824 |
| Pembrolizumab | Other | Phase PHASE3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | ACTIVE_NOT_RECRUITING | NCT06635824 |
| Acasunlimab | Other | Phase PHASE3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | ACTIVE_NOT_RECRUITING | NCT06635824 |
| Epcoritamab | Other | Phase PHASE1 | DLBCL | ACTIVE_NOT_RECRUITING | NCT03625037 |
| Rina-S | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT07166094 |
| Pirtobrutinib | Other | Phase PHASE1 | Relapsed/Refractory Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT04623541 |
| Lenalidomide | Other | Phase PHASE1 | Relapsed/Refractory Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT04623541 |
| Venetoclax | Other | Phase PHASE1 | Relapsed/Refractory Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT04623541 |
| rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone | Other | Phase PHASE1 | Relapsed/Refractory Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT04623541 |
| Epcoritamab | Other | Phase PHASE1 | Relapsed/Refractory Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT04623541 |
| 5-Fluorouracil | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06057038 |
| Carboplatin | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06057038 |
| Cisplatin | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06057038 |
| Pembrolizumab | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06057038 |
| GEN1042 | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06057038 |
| Rituximab and Lenalidomide | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| rituximab, ifosfamide, carboplatin, and etoposide phosphate | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| Lenalidomide | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| Epcoritamab | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| gemcitabine and oxaliplatin | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| rituximab and bendamustine | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| rituximab and lenalidomide | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| PLD | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | NOT_YET_RECRUITING | NCT07564141 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | NOT_YET_RECRUITING | NCT07564141 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | NOT_YET_RECRUITING | NCT07564141 |
| Carboplatin | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | NOT_YET_RECRUITING | NCT07564141 |
| Bevacizumab | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | NOT_YET_RECRUITING | NCT07564141 |
| Rina-S | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | NOT_YET_RECRUITING | NCT07564141 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Pegylated liposomal doxorubicin (PLD) | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Topotecan | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Rina-S | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Rituximab and lenalidomide | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04542824 |
| Epcoritamab (maintenance) | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04542824 |
| Gemcitabine and oxaliplatin | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04542824 |
| Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04542824 |
| Epcoritamab | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04542824 |
| Epcoritamab (monotherapy) | Drug | Phase PHASE1 | Diffuse Large B Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04542824 |
| Paclitaxel | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Pemetrexed | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Nab paclitaxel | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Gemcitabine | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| 5-FU | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Carboplatin | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Cisplatin | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Pembrolizumab | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| GEN1042 | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Rina-S | Other | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07288177 |
| Lenalidomide | Other | Phase PHASE2 | Diffuse Large B-Cell Lymphoma | TERMINATED | NCT05660967 |
| Epcoritamab | Other | Phase PHASE2 | Diffuse Large B-Cell Lymphoma | TERMINATED | NCT05660967 |
| Radiotherapy | Drug | Phase PHASE1 | Non-CNS Tumor | TERMINATED | NCT05491317 |
| Pembrolizumab | Other | Phase PHASE1 | Non-CNS Tumor | TERMINATED | NCT05491317 |
| GEN1042 | Other | Phase PHASE1 | Non-CNS Tumor | TERMINATED | NCT05491317 |
| Gemcitabine and oxaliplatin | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | RECRUITING | NCT06447376 |
| Epcoritamab | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | RECRUITING | NCT06447376 |
| Siltuximab | Other | Phase PHASE1 | Non-Hodgkin Lymphoma | RECRUITING | NCT06447376 |
| Rina-S | Other | Phase PHASE2 | Gastrointestinal Cancers | RECRUITING | NCT07539311 |
| GEN1106 | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT07416123 |
| Pembrolizumab | Other | Phase PHASE2 | Cutaneous Melanoma | TERMINATED | NCT06984328 |
| Acasunlimab | Other | Phase PHASE2 | Cutaneous Melanoma | TERMINATED | NCT06984328 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Pegylated liposomal doxorubicin (PLD) | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Topotecan | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Rina-S | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Pembrolizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Bevacizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Carboplatin | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Rina-S | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| PLD | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | NOT_YET_RECRUITING | NCT07564141 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | NOT_YET_RECRUITING | NCT07564141 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | NOT_YET_RECRUITING | NCT07564141 |
| Carboplatin | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | NOT_YET_RECRUITING | NCT07564141 |
| Bevacizumab | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | NOT_YET_RECRUITING | NCT07564141 |
| Rina-S | Other | Phase PHASE3 | Platinum-Sensitive Ovarian Cancer | NOT_YET_RECRUITING | NCT07564141 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Pegylated liposomal doxorubicin (PLD) | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Topotecan | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Rina-S | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| IC | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT07166094 |
| Paclitaxel | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Pemetrexed | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Nab paclitaxel | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Gemcitabine | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| 5-FU | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Carboplatin | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Cisplatin | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| Pembrolizumab | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| GEN1042 | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT04083599 |
| GEN3018 | Other | Phase PHASE1 | R/R AML | RECRUITING | NCT07384715 |
| CC-99282 | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | RECRUITING | NCT05283720 |
| Polatuzumab Vedotin | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | RECRUITING | NCT05283720 |
| Prednisone | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | RECRUITING | NCT05283720 |
| Doxorubicin Hydrochloride [HCl] | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | RECRUITING | NCT05283720 |
| Cyclophosphamide | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | RECRUITING | NCT05283720 |
| Rituximab | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | RECRUITING | NCT05283720 |
| Ibrutinib | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | RECRUITING | NCT05283720 |
| Lenalidomide | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | RECRUITING | NCT05283720 |
| Epcoritamab | Other | Phase PHASE2 | Non-Hodgkin Lymphoma | RECRUITING | NCT05283720 |
| Rina-S | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT07166094 |
| Epcoritamab | Other | Phase PHASE1 | DLBCL | ACTIVE_NOT_RECRUITING | NCT03625037 |
| Bevacizumab | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07225270 |
| Rina-S | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07225270 |
| Lenalidomide | Other | Phase PHASE2 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05660967 |
| Epcoritamab | Other | Phase PHASE2 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05660967 |
| Rina-S | Other | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07288177 |
| GEN1106 | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT07416123 |
| Rituximab and lenalidomide | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04542824 |
| Epcoritamab (maintenance) | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04542824 |
| Gemcitabine and oxaliplatin | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04542824 |
| Rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04542824 |
| Epcoritamab | Other | Phase PHASE1 | Diffuse Large B Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04542824 |
| Epcoritamab (monotherapy) | Drug | Phase PHASE1 | Diffuse Large B Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04542824 |
| 5-Fluorouracil | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06057038 |
| Carboplatin | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06057038 |
| Cisplatin | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06057038 |
| Pembrolizumab | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06057038 |
| GEN1042 | Other | Phase PHASE1 | Malignant Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06057038 |
| GEN1079 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07387068 |
| Pirtobrutinib | Other | Phase PHASE1 | Relapsed/Refractory Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT04623541 |
| Lenalidomide | Other | Phase PHASE1 | Relapsed/Refractory Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT04623541 |
| Venetoclax | Other | Phase PHASE1 | Relapsed/Refractory Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT04623541 |
| rituximab, cyclophosphamide, doxorubicin, vincristine and prednisone | Other | Phase PHASE1 | Relapsed/Refractory Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT04623541 |
| Epcoritamab | Other | Phase PHASE1 | Relapsed/Refractory Chronic Lymphocytic Leukemia | ACTIVE_NOT_RECRUITING | NCT04623541 |
| Docetaxel | Other | Phase PHASE3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | ACTIVE_NOT_RECRUITING | NCT06635824 |
| Pembrolizumab | Other | Phase PHASE3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | ACTIVE_NOT_RECRUITING | NCT06635824 |
| Acasunlimab | Other | Phase PHASE3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | ACTIVE_NOT_RECRUITING | NCT06635824 |
| Bendamustine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06191744 |
| Obinutuzumab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06191744 |
| Cyclophosphamide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06191744 |
| Vincristine | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06191744 |
| Doxorubicin | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06191744 |
| Lenalidomide | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06191744 |
| Rituximab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06191744 |
| Prednisone | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06191744 |
| Epcoritamab | Other | Phase PHASE3 | Follicular Lymphoma (FL) | RECRUITING | NCT06191744 |
| Pembrolizumab | Other | Phase PHASE2 | Cutaneous Melanoma | ACTIVE_NOT_RECRUITING | NCT06984328 |
| Acasunlimab | Other | Phase PHASE2 | Cutaneous Melanoma | ACTIVE_NOT_RECRUITING | NCT06984328 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Pegylated liposomal doxorubicin (PLD) | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Topotecan | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Rina-S | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Rituximab and Lenalidomide | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| rituximab, ifosfamide, carboplatin, and etoposide phosphate | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| Lenalidomide | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| rituximab, cyclophosphamide, reduced dose of doxorubicin, vincristine, and prednisone | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| Epcoritamab | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| gemcitabine and oxaliplatin | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| rituximab, cytarabine, dexamethasone, and oxaliplatin/carboplatin | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| rituximab and bendamustine | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| rituximab and lenalidomide | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone | Other | Phase PHASE1 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04663347 |
| Rina-S | Other | Phase PHASE2 | Gastrointestinal Cancers | RECRUITING | NCT07539311 |
| GEN1107 | Other | Phase PHASE1 | Endometrial Cancer | TERMINATED | NCT06171789 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Pegylated liposomal doxorubicin (PLD) | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Topotecan | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Rina-S | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Epcoritamab | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | RECRUITING | NCT06458439 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Pegylated liposomal doxorubicin (PLD) | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Topotecan | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Rina-S | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Epcoritamab | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | RECRUITING | NCT06458439 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Pegylated liposomal doxorubicin (PLD) | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Topotecan | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Rina-S | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Epcoritamab | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | RECRUITING | NCT06458439 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Pegylated liposomal doxorubicin (PLD) | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Topotecan | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Rina-S | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Pembrolizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Bevacizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Carboplatin | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Rina-S | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Epcoritamab | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | RECRUITING | NCT06458439 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Pegylated liposomal doxorubicin (PLD) | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Topotecan | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Rina-S | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Pembrolizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Bevacizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Carboplatin | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Rina-S | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Epcoritamab | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | RECRUITING | NCT06458439 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Pegylated liposomal doxorubicin (PLD) | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Topotecan | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Rina-S | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Pembrolizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Bevacizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Carboplatin | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Rina-S | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Epcoritamab | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | RECRUITING | NCT06458439 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Pegylated liposomal doxorubicin (PLD) | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Topotecan | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Rina-S | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Pembrolizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Bevacizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Carboplatin | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Rina-S | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Epcoritamab | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | RECRUITING | NCT06458439 |
| Pembrolizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Bevacizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Carboplatin | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Rina-S | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Pembrolizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Bevacizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Carboplatin | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Rina-S | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Pembrolizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Bevacizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Carboplatin | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Rina-S | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Pembrolizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Bevacizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Carboplatin | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Rina-S | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Pembrolizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Bevacizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Carboplatin | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Rina-S | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Pembrolizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Bevacizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Carboplatin | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Rina-S | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Pegylated liposomal doxorubicin (PLD) | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Topotecan | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Rina-S | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Investigator's Choice Chemotherapy | Drug | Phase PHASE3 | Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04628494 |
| Epcoritamab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04628494 |
| Rituximab | Other | Phase PHASE2 | Follicular Lymphoma | RECRUITING | NCT05783609 |
| Epcoritamab | Other | Phase PHASE2 | Follicular Lymphoma | RECRUITING | NCT05783609 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Pegylated liposomal doxorubicin (PLD) | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Topotecan | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Rina-S | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Investigator's Choice Chemotherapy | Drug | Phase PHASE3 | Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04628494 |
| Epcoritamab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04628494 |
| Rituximab | Other | Phase PHASE2 | Follicular Lymphoma | RECRUITING | NCT05783609 |
| Epcoritamab | Other | Phase PHASE2 | Follicular Lymphoma | RECRUITING | NCT05783609 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Pegylated liposomal doxorubicin (PLD) | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Topotecan | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Rina-S | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Investigator's Choice Chemotherapy | Drug | Phase PHASE3 | Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04628494 |
| Epcoritamab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04628494 |
| Rituximab | Other | Phase PHASE2 | Follicular Lymphoma | RECRUITING | NCT05783609 |
| Epcoritamab | Other | Phase PHASE2 | Follicular Lymphoma | RECRUITING | NCT05783609 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Pegylated liposomal doxorubicin (PLD) | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Topotecan | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Rina-S | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Investigator's Choice Chemotherapy | Drug | Phase PHASE3 | Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04628494 |
| Epcoritamab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04628494 |
| Rituximab | Other | Phase PHASE2 | Follicular Lymphoma | RECRUITING | NCT05783609 |
| Epcoritamab | Other | Phase PHASE2 | Follicular Lymphoma | RECRUITING | NCT05783609 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Pegylated liposomal doxorubicin (PLD) | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Topotecan | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Rina-S | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | NOT_YET_RECRUITING | NCT07604766 |
| Investigator's Choice Chemotherapy | Drug | Phase PHASE3 | Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04628494 |
| Epcoritamab | Other | Phase PHASE3 | Diffuse Large B-cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT04628494 |
| Rituximab | Other | Phase PHASE2 | Follicular Lymphoma | RECRUITING | NCT05783609 |
| Epcoritamab | Other | Phase PHASE2 | Follicular Lymphoma | RECRUITING | NCT05783609 |
| Premedication | Drug | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| GEN1057 | Other | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| Premedication | Drug | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| GEN1057 | Other | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| Premedication | Drug | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| GEN1057 | Other | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| Premedication | Drug | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| GEN1057 | Other | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| Premedication | Drug | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| GEN1057 | Other | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| Premedication | Drug | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| GEN1057 | Other | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| Premedication | Drug | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| GEN1057 | Other | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| Premedication | Drug | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| GEN1057 | Other | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| Daratumumab | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| GEN3014 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| Premedication | Drug | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| GEN1057 | Other | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| Daratumumab | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| GEN3014 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| Premedication | Drug | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| GEN1057 | Other | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| Daratumumab | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| GEN3014 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| Premedication | Drug | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| GEN1057 | Other | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| Daratumumab | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| GEN3014 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| Premedication | Drug | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| GEN1057 | Other | Phase PHASE1 | Advanced Malignant Solid Tumors | TERMINATED | NCT06573294 |
| Daratumumab | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| GEN3014 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| Daratumumab | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| GEN3014 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| Daratumumab | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| GEN3014 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| Daratumumab | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| GEN3014 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| Daratumumab | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| GEN3014 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| Daratumumab | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| GEN3014 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| Daratumumab | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| GEN3014 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| Daratumumab | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| GEN3014 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| Daratumumab | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| GEN3014 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| Daratumumab | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| GEN3014 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| Daratumumab | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| GEN3014 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| Daratumumab | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| GEN3014 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| Rina-S | Other | Phase PHASE2 | Gastrointestinal Cancers | RECRUITING | NCT07539311 |
| zalutumumab | Other | Phase PHASE2 | Non-small Cell Lung Cancer | WITHDRAWN | NCT01449357 |
| zalutumumab | Other | Phase PHASE2 | Non-small Cell Lung Cancer | WITHDRAWN | NCT01449357 |
| Radiotherapy | Drug | Phase PHASE2 | Non Small Cell Lung Cancer | TERMINATED | NCT00460551 |
| Induction chemotherapy | Drug | Phase PHASE2 | Non Small Cell Lung Cancer | TERMINATED | NCT00460551 |
| Zalutumumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | TERMINATED | NCT00460551 |
| Radiotherapy | Drug | Phase PHASE2 | Non Small Cell Lung Cancer | TERMINATED | NCT00460551 |
| Induction chemotherapy | Drug | Phase PHASE2 | Non Small Cell Lung Cancer | TERMINATED | NCT00460551 |
| Zalutumumab | Other | Phase PHASE2 | Non Small Cell Lung Cancer | TERMINATED | NCT00460551 |
| Radiotherapy | Drug | Phase PHASE1 | Head and Neck Cancer | TERMINATED | NCT00401401 |
| cisplatin | Other | Phase PHASE1 | Head and Neck Cancer | TERMINATED | NCT00401401 |
| zalutumumab | Other | Phase PHASE1 | Head and Neck Cancer | TERMINATED | NCT00401401 |
| Radiotherapy | Drug | Phase PHASE1 | Head and Neck Cancer | TERMINATED | NCT00401401 |
| cisplatin | Other | Phase PHASE1 | Head and Neck Cancer | TERMINATED | NCT00401401 |
| zalutumumab | Other | Phase PHASE1 | Head and Neck Cancer | TERMINATED | NCT00401401 |
| Rina-S | Other | Phase PHASE2 | Gastrointestinal Cancers | RECRUITING | NCT07539311 |
| Rina-S | Other | Phase PHASE2 | Gastrointestinal Cancers | RECRUITING | NCT07539311 |
| Rina-S | Other | Phase PHASE2 | Gastrointestinal Cancers | RECRUITING | NCT07539311 |
| Control | Other | Phase PHASE3 | Head and Neck Cancer | COMPLETED | NCT00382031 |
| Zalutumumab | Other | Phase PHASE3 | Head and Neck Cancer | COMPLETED | NCT00382031 |
| Control | Other | Phase PHASE3 | Head and Neck Cancer | COMPLETED | NCT00382031 |
| Zalutumumab | Other | Phase PHASE3 | Head and Neck Cancer | COMPLETED | NCT00382031 |
| HuMax-CD4 | Other | Phase PHASE2 | Cutaneous T-Cell Lymphoma | COMPLETED | NCT00071084 |
| Rina-S | Other | Phase PHASE2 | Gastrointestinal Cancers | RECRUITING | NCT07539311 |
| Tisotumab vedotin (HuMax-TF-ADC) | Other | Phase PHASE1 | Ovary Cancer | COMPLETED | NCT02552121 |
| Tisotumab vedotin (HuMax-TF-ADC) | Other | Phase PHASE1 | Ovary Cancer | COMPLETED | NCT02552121 |
| Tisotumab vedotin (HuMax-TF-ADC) | Other | Phase PHASE1 | Ovary Cancer | COMPLETED | NCT02552121 |
| Tisotumab Vedotin | Other | Phase PHASE2 | Ovary Cancer | COMPLETED | NCT03245736 |
| Tisotumab Vedotin | Other | Phase PHASE2 | Ovary Cancer | COMPLETED | NCT03245736 |
| Tisotumab Vedotin | Other | Phase PHASE2 | Ovary Cancer | COMPLETED | NCT03245736 |
| Tisotumab Vedotin (HuMax-TF-ADC) | Other | Phase PHASE1 | Ovary Cancer | COMPLETED | NCT02001623 |
| Tisotumab Vedotin (HuMax-TF-ADC) | Other | Phase PHASE1 | Ovary Cancer | COMPLETED | NCT02001623 |
| Tisotumab Vedotin (HuMax-TF-ADC) | Other | Phase PHASE1 | Ovary Cancer | COMPLETED | NCT02001623 |
| tisotumab vedotin | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT03913741 |
| tisotumab vedotin | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT03913741 |
| Humax-CD4 | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00042406 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00042406 |
| HuMax-CD4 | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00042406 |
| Humax-CD4 | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00042406 |
| Placebo | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00042406 |
| HuMax-CD4 | Other | Phase PHASE2 | Rheumatoid Arthritis | TERMINATED | NCT00042406 |
| tisotumab vedotin | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT03657043 |
| tisotumab vedotin | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT03657043 |
| tisotumab vedotin | Other | Phase PHASE2 | Ovarian Cancer | COMPLETED | NCT03657043 |
| HuMax-CD4 | Other | Phase PHASE2 | Cutaneous T-Cell Lymphoma | COMPLETED | NCT00071071 |
| HuMax-CD4 | Other | Phase PHASE2 | Cutaneous T-Cell Lymphoma | COMPLETED | NCT00071071 |
| Epcoritamab | Other | Preclinical | Large B-cell Lymphoma | APPROVED_FOR_MARKETING | NCT05733650 |
| Zalutumumab | Other | Phase PHASE1 | Head and Neck Neoplasms | COMPLETED | NCT00093041 |
| Zalutumumab | Other | Phase PHASE1 | Head and Neck Neoplasms | COMPLETED | NCT00093041 |
| Zalutumumab | Other | Phase PHASE1 | Colorectal Cancer | TERMINATED | NCT00677924 |
| Zalutumumab | Other | Phase PHASE1 | Colorectal Cancer | TERMINATED | NCT00677924 |
| tisotumab vedotin | Other | Phase PHASE2 | Cervical Cancer | COMPLETED | NCT03438396 |
| tisotumab vedotin | Other | Phase PHASE2 | Cervical Cancer | COMPLETED | NCT03438396 |
| GEN1029 (HexaBody®-DR5/DR5) | Other | Phase PHASE1 | Colorectal Cancer | TERMINATED | NCT03576131 |
| Enapotamab vedotin (HuMax-AXL-ADC) | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT02988817 |
| Enapotamab vedotin (HuMax-AXL-ADC) | Other | Phase PHASE1 | Ovarian Cancer | COMPLETED | NCT02988817 |
| zalutumumab | Other | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT01054625 |
| zalutumumab | Other | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT01054625 |
| zalutumumab | Other | Phase PHASE1 | Head and Neck Cancer | COMPLETED | NCT01054625 |
| Zalutumumab | Other | Phase PHASE1 | Head and Neck Cancer | TERMINATED | NCT00707655 |
| Zalutumumab | Other | Phase PHASE2 | Head and Neck Cancer | COMPLETED | NCT00542308 |
| Investigation agent 3 | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Investigation agent 2 | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Prednisone | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Cyclophosphamide | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Doxorubicin | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Vincristine | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Bendamustine | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Obinutuzumab | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Rituximab | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Lenalidomide | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Epcoritamab | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Investigation agent 3 | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Investigation agent 2 | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Prednisone | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Cyclophosphamide | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Doxorubicin | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Vincristine | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Bendamustine | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Obinutuzumab | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Rituximab | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Lenalidomide | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Epcoritamab | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Investigation agent 3 | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Investigation agent 2 | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Prednisone | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Cyclophosphamide | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Doxorubicin | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Vincristine | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Bendamustine | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Obinutuzumab | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Rituximab | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Lenalidomide | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Epcoritamab | Other | Phase PHASE2 | Relapsed Follicular Lymphoma | RECRUITING | NCT05848765 |
| Epcoritamab | Other | Phase PHASE1 | Diffuse Large B-cell Lymphoma | TERMINATED | NCT04358458 |
| GEN3009 | Other | Phase PHASE1 | Diffuse Large B-cell Lymphoma | TERMINATED | NCT04358458 |
| Epcoritamab | Other | Phase PHASE1 | Diffuse Large B-cell Lymphoma | TERMINATED | NCT04358458 |
| GEN3009 | Other | Phase PHASE1 | Diffuse Large B-cell Lymphoma | TERMINATED | NCT04358458 |
| Prednisone | Other | Phase PHASE3 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05578976 |
| Doxorubicin | Other | Phase PHASE3 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05578976 |
| Vincristine | Other | Phase PHASE3 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05578976 |
| Rituximab | Other | Phase PHASE3 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05578976 |
| Cyclophosphamide | Other | Phase PHASE3 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05578976 |
| Epcoritamab | Other | Phase PHASE3 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05578976 |
| Prednisone | Other | Phase PHASE3 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05578976 |
| Doxorubicin | Other | Phase PHASE3 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05578976 |
| Vincristine | Other | Phase PHASE3 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05578976 |
| Rituximab | Other | Phase PHASE3 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05578976 |
| Cyclophosphamide | Other | Phase PHASE3 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05578976 |
| Epcoritamab | Other | Phase PHASE3 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05578976 |
| Prednisone | Other | Phase PHASE3 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05578976 |
| Doxorubicin | Other | Phase PHASE3 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05578976 |
| Vincristine | Other | Phase PHASE3 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05578976 |
| Rituximab | Other | Phase PHASE3 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05578976 |
| Cyclophosphamide | Other | Phase PHASE3 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05578976 |
| Epcoritamab | Other | Phase PHASE3 | Diffuse Large B-Cell Lymphoma | ACTIVE_NOT_RECRUITING | NCT05578976 |
| Rina-S | Other | Phase PHASE2 | Gastrointestinal Cancers | RECRUITING | NCT07539311 |
| Rina-S | Other | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07288177 |
| Epcoritamab | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | RECRUITING | NCT06458439 |
| Epcoritamab | Other | Phase PHASE2 | Lymphoma, Non-Hodgkin | RECRUITING | NCT06458439 |
| Pembrolizumab | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04937153 |
| Acasunlimab | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04937153 |
| Pembrolizumab | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04937153 |
| Acasunlimab | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04937153 |
| Pembrolizumab | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04937153 |
| Acasunlimab | Other | Phase PHASE1 | Solid Tumor | COMPLETED | NCT04937153 |
| GEN3017 | Other | Phase PHASE1 | Classical Hodgkin Lymphoma | TERMINATED | NCT06018129 |
| GEN3017 | Other | Phase PHASE1 | Classical Hodgkin Lymphoma | TERMINATED | NCT06018129 |
| GEN3017 | Other | Phase PHASE1 | Classical Hodgkin Lymphoma | TERMINATED | NCT06018129 |
| Daratumumab | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| GEN3014 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| Daratumumab | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| GEN3014 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| Daratumumab | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| GEN3014 | Other | Phase PHASE1 | Relapsed or Refractory Multiple Myeloma (RRMM) | TERMINATED | NCT04824794 |
| Epcoritamab | Other | Phase PHASE2 | CLL/SLL | RECRUITING | NCT07108998 |
| Epcoritamab | Other | Phase PHASE2 | CLL/SLL | RECRUITING | NCT07108998 |
| GEN1078 | Other | Phase PHASE1 | Malignant Solid Tumor | TERMINATED | NCT06771921 |
| GEN1078 | Other | Phase PHASE1 | Malignant Solid Tumor | TERMINATED | NCT06771921 |
| Epcoritamab | Other | Phase PHASE2 | Follicular Lymphoma | RECRUITING | NCT06563596 |
| Rituximab | Other | Phase PHASE2 | Follicular Lymphoma | RECRUITING | NCT06563596 |
| Zanubrutinib | Other | Phase PHASE2 | Follicular Lymphoma | RECRUITING | NCT06563596 |
| Epcoritamab | Other | Phase PHASE2 | Relapsed Large B-cell Lymphoma | RECRUITING | NCT06811272 |
| Epcoritamab | Other | Phase PHASE2 | Relapsed Large B-cell Lymphoma | RECRUITING | NCT06811272 |
| GEN1107 | Other | Phase PHASE1 | Endometrial Cancer | TERMINATED | NCT06171789 |
| GEN1107 | Other | Phase PHASE1 | Endometrial Cancer | TERMINATED | NCT06171789 |
| Rina-S | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT07166094 |
| Rina-S | Other | Phase PHASE3 | Endometrial Cancer | RECRUITING | NCT07166094 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Pegylated liposomal doxorubicin (PLD) | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Topotecan | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Rina-S | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Gemcitabine | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Pegylated liposomal doxorubicin (PLD) | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Topotecan | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Paclitaxel | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Rina-S | Other | Phase PHASE3 | Platinum-resistant Ovarian Cancer | ACTIVE_NOT_RECRUITING | NCT06619236 |
| Premedication | Drug | Phase PHASE1 | Advanced Malignant Solid Tumors | RECRUITING | NCT06573294 |
| GEN1057 | Other | Phase PHASE1 | Advanced Malignant Solid Tumors | RECRUITING | NCT06573294 |
| GEN1047 is a bispecific antibody that induces T-cell mediated cytotoxicity of B7H4-positive tumor cells. | Other | Phase PHASE1 | Breast Cancer, Breast Neoplasms | ACTIVE_NOT_RECRUITING | NCT05180474 |
| GEN1079 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07387068 |
| GEN1160 | Other | Phase PHASE1 | Renal Cell Carcinoma | TERMINATED | NCT05721222 |
| Epcoritamab | Other | Phase PHASE2 | Waldenstrom Macroglobulinemia | RECRUITING | NCT06510491 |
| Epcoritamab | Other | Phase PHASE2 | Lymphoma | RECRUITING | NCT06510361 |
| Epcoritamab | Other | Phase PHASE2 | Lymphoma | RECRUITING | NCT06510361 |
| Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts) | Drug | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03917381 |
| Acasunlimab in combination with pembrolizumab (in a separate expansion cohort) | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03917381 |
| Acasunlimab in combination with docetaxel (in a single expansion cohort) | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03917381 |
| Acasunlimab | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03917381 |
| Acasunlimab in combination with pembrolizumab and standard chemotherapy (in separate expansion cohorts) | Drug | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03917381 |
| Acasunlimab in combination with pembrolizumab (in a separate expansion cohort) | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03917381 |
| Acasunlimab in combination with docetaxel (in a single expansion cohort) | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03917381 |
| Acasunlimab | Other | Phase PHASE1 | Solid Tumors | ACTIVE_NOT_RECRUITING | NCT03917381 |
| Pembrolizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Bevacizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Carboplatin | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Rina-S | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Pembrolizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Bevacizumab | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Carboplatin | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| Rina-S | Other | Phase PHASE1 | High Grade Epithelial Ovarian Cancer | RECRUITING | NCT05579366 |
| GEN1106 | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT07416123 |
| GEN3018 | Other | Phase PHASE1 | R/R AML | RECRUITING | NCT07384715 |
| GEN3018 | Other | Phase PHASE1 | R/R AML | RECRUITING | NCT07384715 |
| Rina-S | Other | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07288177 |
| Rina-S | Other | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07288177 |
| Bevacizumab | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07225270 |
| Rina-S | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07225270 |
| Bevacizumab | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07225270 |
| Rina-S | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07225270 |
| Bevacizumab | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07225270 |
| Rina-S | Other | Phase PHASE3 | Ovarian Cancer | RECRUITING | NCT07225270 |
| Pembrolizumab | Other | Phase PHASE2 | Cutaneous Melanoma | ACTIVE_NOT_RECRUITING | NCT06984328 |
| Acasunlimab | Other | Phase PHASE2 | Cutaneous Melanoma | ACTIVE_NOT_RECRUITING | NCT06984328 |
| Pembrolizumab | Other | Phase PHASE2 | Cutaneous Melanoma | ACTIVE_NOT_RECRUITING | NCT06984328 |
| Acasunlimab | Other | Phase PHASE2 | Cutaneous Melanoma | ACTIVE_NOT_RECRUITING | NCT06984328 |
| GEN1286 | Other | Phase PHASE1 | Advanced Solid Tumor | ACTIVE_NOT_RECRUITING | NCT06685068 |
| Docetaxel | Other | Phase PHASE3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | ACTIVE_NOT_RECRUITING | NCT06635824 |
| Pembrolizumab | Other | Phase PHASE3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | ACTIVE_NOT_RECRUITING | NCT06635824 |
| Acasunlimab | Other | Phase PHASE3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | ACTIVE_NOT_RECRUITING | NCT06635824 |
| Docetaxel | Other | Phase PHASE3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | ACTIVE_NOT_RECRUITING | NCT06635824 |
| Pembrolizumab | Other | Phase PHASE3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | ACTIVE_NOT_RECRUITING | NCT06635824 |
| Acasunlimab | Other | Phase PHASE3 | PD-L1-positive, Locally Advanced (Unresectable Stage IIIB/C) or Metastatic NSCLC | ACTIVE_NOT_RECRUITING | NCT06635824 |
| Epcoritamab | Other | Phase PHASE2 | Large Cell Lymphoma, Diffuse | RECRUITING | NCT05852717 |
| GDP | Other | Phase PHASE2 | Large Cell Lymphoma, Diffuse | RECRUITING | NCT05852717 |
| AutoSCT OR CAR T-cell Therapy | Drug | Phase PHASE2 | Large Cell Lymphoma, Diffuse | RECRUITING | NCT05852717 |
| Epcoritamab | Other | Phase PHASE2 | Large Cell Lymphoma, Diffuse | RECRUITING | NCT05852717 |
| GDP | Other | Phase PHASE2 | Large Cell Lymphoma, Diffuse | RECRUITING | NCT05852717 |
| AutoSCT OR CAR T-cell Therapy | Drug | Phase PHASE2 | Large Cell Lymphoma, Diffuse | RECRUITING | NCT05852717 |
| Premedication | Drug | Phase PHASE1 | Advanced Malignant Solid Tumors | RECRUITING | NCT06573294 |
| GEN1057 | Other | Phase PHASE1 | Advanced Malignant Solid Tumors | RECRUITING | NCT06573294 |
| GEN1286 | Other | Phase PHASE1 | Advanced Solid Tumor | TERMINATED | NCT06685068 |
| GEN1106 | Other | Phase PHASE1 | Solid Tumors | RECRUITING | NCT07416123 |
| GEN1079 | Other | Phase PHASE1 | Advanced Solid Tumors | RECRUITING | NCT07387068 |
| Rina-S | Other | Phase PHASE2 | Non-small Cell Lung Cancer (NSCLC) | RECRUITING | NCT07288177 |
Total products: 697